Oncocross온코크로스

Oncocross is an AI drug-discovery company with heavy losses, a shrinking revenue base and a share price down sharply over the past year.

Oncocross sells AI analysis services to drug developers, centred on its RAPTOR AI platform and Neo Omics proteomics services. On a trailing twelve-month basis to H1 2026 it reported revenue of about ₩0.4B against an operating loss of about ₩9.8B, with borrowings of about ₩8.6B against cash of about ₩0.3B. The share price closed at ₩3,110 on 27 October 2026, down 62.7% over one year and 14.3% over one month.

What stands out

• Revenue fell from ₩1.07T in 2024 to ₩0.37T in 2025, and trailing revenue to H1 2026 is only about ₩0.4B, so the business is very small relative to its losses.
• Operating margin is deeply negative (about -2,474% trailing), and free cash flow was about -₩7.2B over the same period.
• Liabilities are 138% of equity and borrowings are roughly 30 times cash, which the data flags as a balance-sheet strain.
• The company's own DCF-based fair value model gives ₩883 per share, well below the ₩3,110 close; the data does not explain the gap in detail.
• Recent headlines cover new joint drug-development agreements with April Bio, OmicsAI and Curi-Jin, announced in October 2026.

What to watch

• Filings on convertible bond conversion price adjustments and the early buy-back of own convertible bonds, which bear on dilution and cash needs.
• The next quarterly or annual report, to see whether revenue recovers from the 2025 drop and whether losses narrow.
• Foreign ownership, which fell from 2.6% to 1.8% over the last 60 days, and the large share-price decline over the year.